Eyegate Pharmaceuticals, Inc. (EYEG) Sees Strong Trading Volume
Shares of Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) saw an uptick in trading volume on Tuesday . 1,678,035 shares were traded during trading, an increase of 656% from the previous session’s volume of 221,908 shares.The stock last traded at $1.19 and had previously closed at $1.02.
Several research firms have recently weighed in on EYEG. HC Wainwright set a $6.00 price objective on shares of Eyegate Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 2nd. Noble Financial restated a “buy” rating on shares of Eyegate Pharmaceuticals in a research report on Friday, May 19th.
The firm’s 50-day moving average is $1.13 and its 200-day moving average is $1.78. The firm’s market capitalization is $19.61 million.
A hedge fund recently raised its stake in Eyegate Pharmaceuticals stock. Vanguard Group Inc. boosted its stake in shares of Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) by 0.8% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 247,319 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,988 shares during the period. Vanguard Group Inc. owned about 2.27% of Eyegate Pharmaceuticals worth $339,000 at the end of the most recent quarter. 12.99% of the stock is owned by institutional investors.
About Eyegate Pharmaceuticals
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.